Literature DB >> 19030778

Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets.

Atsuo Inoue1, Kenji A Takahashi, Osam Mazda, Yuji Arai, Masazumi Saito, Tsunao Kishida, Masaharu Shin-Ya, Toru Morihara, Hitoshi Tonomura, Kei Sakao, Jiro Imanishi, Toshikazu Kubo.   

Abstract

RNA interference (RNAi) provides a powerful means of sequence-specific gene silencing. Several studies show that RNAi may provide promising strategies to treat human diseases by suppressing disease responsible genes in vivo. In locomotor diseases, the progression of collagen-induced arthritis (CIA) is suppressed by tumor necrosis factor-alpha (TNF-alpha)-specific small interfering RNA (siRNA) delivered into the joint. The aim of this study, is to compare the effects of intraarticularly administered siRNAs targeting TNF-alpha, interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and receptor activator of NF-kappaB ligand (RANKL) on CIA in rats. We confirmed that the silencing effects of siRNA duplexes specific for rat TNF-alpha, IL-1beta, IL-6 and RANKL in vitro. Each siRNA was also delivered into the knee joint of CIA rats by the in vivo electroporation method 7, 10, 13 and 16 days after immunization with collagen. Local delivery of TNF-alpha or IL-1beta-specific siRNA ameliorated CIA in rats effectively at the gross morphological, radiographical and histological evaluations. Our results suggested that TNF-alpha and IL-1beta were the cytokines to be targeted in the joint for the treatment of rheumatoid arthritis. The in vivo siRNA transfection method may be useful for selection of target molecules to be silenced for treatment of joint diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19030778     DOI: 10.1007/s10165-008-0131-3

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  5 in total

1.  Targeted delivery of siRNA to macrophages for anti-inflammatory treatment.

Authors:  Sang-Soo Kim; Chunting Ye; Priti Kumar; Isaac Chiu; Sandesh Subramanya; Haoquan Wu; Premlata Shankar; N Manjunath
Journal:  Mol Ther       Date:  2010-03-09       Impact factor: 11.454

2.  Adenovirus-Mediated Small Interfering RNA Targeting TAK1 Ameliorates Joint Inflammation with Collagen-Induced Arthritis in Mice.

Authors:  Xinjing Luo; Yongfeng Chen; Guoju Lv; Zhidong Zhou; Jie Chen; Xuanrong Mo; Jiangwen Xie
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

Review 3.  siRNA-based therapeutic approaches for rheumatic diseases.

Authors:  Florence Apparailly; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

4.  RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells.

Authors:  Ling-Qing Yuan; Jia-Hua Zhu; Hua-Wen Wang; Qiu-Hua Liang; Hui Xie; Xian-Ping Wu; Hua Zhou; Rong-Rong Cui; Zhi-Feng Sheng; Hou-De Zhou; Xiao Zhu; Guan-Ying Liu; You-Shuo Liu; Er-Yuan Liao
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

5.  Transplantation of IL-1β siRNA-modified bone marrow mesenchymal stem cells ameliorates type II collagen-induced rheumatoid arthritis in rats.

Authors:  Shifeng Pan; Xuan Dong; Yan Wang; Tiansheng Zhou; Yuting Liu; An Zhou; Hua Xing
Journal:  Exp Ther Med       Date:  2021-12-14       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.